This study evaluated the safety, tolerability, and pharmacokinetics of a novel oral amphotericin B (AmB) formulation (iCo-019) following single doses to healthy humans. The data from this study suggest that iCo-019 has a long circulation time and systemic exposure without the associated gastrointestinal, liver, and kidney toxicity associated with AmB. This novel oral AmB formulation can serve as a new treatment strategy to overcome the limitations of the use of parenterally administered AmB products.

中文翻译：

---

向健康人类受试者单次给药后，新型口服两性霉素B制剂（iCo-019）的安全性，耐受性和药代动力学：肠胃外两性霉素B给药的替代方法。

这项研究评估了单剂量对健康人类的新型口服两性霉素B（AmB）制剂（iCo-019）的安全性，耐受性和药代动力学。这项研究的数据表明，iCo-019具有较长的循环时间和全身性暴露，而没有与AmB相关的胃肠道，肝脏和肾脏毒性。这种新颖的口服AmB制剂可以作为一种新的治疗策略，以克服使用非肠道给药AmB产品的局限性。